The prognostic value of lymph node ratio in comparison to positive lymph node count in penile squamous cell carcinoma.

Penile cancer is a rare male neoplasm with a wide variation in its global incidence. In this study, the prognostic value of lymph node ratio (LNR) was compared to that of positive lymph node count (PLNC) in penile squamous cell carcinoma.

A total of 249 patients with penile squamous cell carcinoma were enrolled from The Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. The X-tile program was used to calculate the optimal cut-off values of LNR and PLNC that discriminate survival. We used the χ2 or the Fisher exact probability test to assess the association between clinical-pathological characteristics and LNR or PLNC. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors for survival. Spearman correlation analysis was used to determine the correlation between LNR and PLNC.

We found that patients with high LNR tended to have advanced N stage, the 7th AJCC stage, and higher pathological grade, while patients with high PLNC had advanced N stage and the 7th AJCC stage. Univariate Cox regression analysis revealed that the N stage, M stage, the 7th AJCC stage, lymph-vascular invasion, LNR, and PLNC were significantly associated with prognosis. Multivariate Cox regression analysis demonstrated that LNR rather than PLNC was an independent prognostic factor for cancer-specific survival. Subgroup analysis of node-positive patients showed that LNR was associated with CSS, while PLNC was not.

LNR was a better predictor for long-term prognosis than PLNC in patients with penile squamous cell carcinoma.

International urology and nephrology. 2021 Sep 28 [Epub ahead of print]

Jiajie Yu, Qian Long, Zhiqiang Zhang, Shufen Liao, Fufu Zheng

Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No.58 the 2nd Zhongshan Road, Guangzhou, 510080, China., State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China., Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No.58 the 2nd Zhongshan Road, Guangzhou, 510080, China. .